Smoking marijuana reduces cancer risk

“Marijuana reduces cancer risk and kills existing tumors”

People smoke a joint during a demonstration organised by the CIRC (research and information center) and entitled 'L'appel du 18 juin' (the call of June 18) to claim for the legalization of the use of marijuana and hashish, on June 18, 2011 at the Parc de la Villette in Paris. The 'Appel du 18 Joint' uses a play on words to make their point, coming on the same day as France celebrates the 'Appel du 18 Juin' or Call of 18 June, when Charles de Gaulle called for resistance against collaborationist Vichy government in 1940. AFP PHOTO / FRED DUFOUR

“This may be hard to believe — as we’re fairly accustomed to the notion that inhaling smoke is always bad for your health — but research shows smoking marijuana actually decreases the risk for developing lung cancer.

According to multiple study findings published on Cancer.gov, “Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.”

Dr. Donald Tashkin, professor emeritus of medicine at UCLA, also recently revealed to LA Weekly that after 30 years of studying the effects of marijuana smoke on lung function, he did not find any association between lung cancer and smoking weed.

Smoking marijuana doesn’t lead to impaired lung function either

Tashkin also found smoking marijuana does not lead to impaired lung function even after years of habitual use.”

More: http://extract.suntimes.com/information-resources/10/153/892/smoking-marijuana-reduces-cancer-risk

“Cannabis has been shown to kill cancer cells in the laboratory. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.” http://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq#section/all

http://www.thctotalhealthcare.com/category/cancer/

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

Image result for Eur J Pharmacol.

“Cannabinoids have been used for many centuries to ease pain and in the past decade, the endocannabinoid system has been implicated in a number of pathophysiological conditions, such as mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis.

Several studies have demonstrated that cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do not produce the typical toxic effects of conventional chemotherapies, there is considerable merit in the development of cannabinoids as potential anticancer therapies.

Whilst the presence of psychoactive effects of cannabinoids could prevent any progress in this field, recent studies have shown the value of the non-psychoactive components of cannabinoids in activating apoptotic pathways, inducing anti-proliferative and anti-angiogenic effects.

The aforementioned effects are suggested to be through pathways such as ERK, Akt, mitogen-activated protein kinase (MAPK) pathways, phosphoinositide 3-kinase (PI3K) pathways and hypoxia inducible factor 1 (HIF1), all of which are important contributors to the hallmarks of cancer.

Many important questions still remain unanswered or are poorly addressed thus necessitating further research at basic pre-clinical and clinical levels. In this review, we address these issues with a view to identifying the key challenges that future research needs to address.”

http://www.ncbi.nlm.nih.gov/pubmed/26852955

http://www.thctotalhealthcare.com/category/cancer/

Medicinal cannabis.

“A number of therapeutic uses of cannabis and its derivatives have been postulated from preclinical investigations.

Possible clinical indications include spasticity and pain in multiple sclerosis, cancer-associated nausea and vomiting, cancer pain and HIV neuropathy.

Controversies lie in how to produce, supply and administer cannabinoid products.

Introduction of cannabinoids therapeutically should be supported by a regulatory and educational framework that minimises the risk of harm to patients and the community.

The Regulator of Medicinal Cannabis Bill 2014 is under consideration in Australia to address this.

Nabiximols is the only cannabinoid on the Australian Register of Therapeutic Goods at present, although cannabidiol has been recommended for inclusion in Schedule 4.”

http://www.ncbi.nlm.nih.gov/pubmed/26843715

“There is some evidence of therapeutic benefit for cannabis products in defined patient populations.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674028/

Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveal a Mechanism for Regulation of Tumor Progression.

“The G-protein-coupled chemokine receptor, CXCR4, generates signals that lead to cell migration, cell proliferation, and other survival mechanisms which result in the metastatic spread of primary tumor cells to distal organs.

Numerous studies have demonstrated that CXCR4 can form homodimers, or can heterodimerize with other GPCRs to form receptor complexes that can amplify or decrease the signaling capacity of each individual receptor.

Using biophysical and biochemical approaches, we found that CXCR4 can form an induced heterodimer with cannabinoid receptor 2 (CB2) in human breast and prostate cancer cells.

Simultaneous, agonist-dependent activation of CXCR4 and CB2 resulted in reduced CXCR4-mediated expression of phosphorylated ERK1/2, and ultimately, reduced cancer cell functions such as calcium mobilization and cellular chemotaxis.

Given that treatment with cannabinoids has been shown to reduce invasiveness of cancer cells, as well as CXCR4-mediated migration of immune cells, it is therefore plausible that CXCR4 signaling can be silenced through a physical heterodimeric association with CB2, thereby inhibiting subsequent functions of CXCR4.

Taken together, the data illustrates a mechanism by which the cannabinoid system can negatively modulate CXCR4 receptor function, and perhaps, tumor progression.”

http://www.ncbi.nlm.nih.gov/pubmed/26841863

Granite City Man Claims Cannabis Oil Cured His ‘Incurable’ Cancer

Darren Miller looks over medical records showing he is cancer-free just months after being diagnosed with "incurable, inoperable" cancer. Miller claims the use of cannabis oil completely wiped out the cancer in his system. (KMOX/Brett Blume)

“Darren Miller is ready to enjoy his second chance at life.

The 50-year-old Granite City man is putting out the word that a steady diet of cannabis oil coupled with chemotherapy wiped out what doctors had only months earlier diagnosed as “incurable, inoperable” lung and pericardial heart sac cancer.

He’d basically been given about a year to live, with chemo.

“Glad to be here, glad to be anywhere with the diagnosis I had,” Miller said by way of introduction during a sitdown with KMOX News.

He carried with him a stack of medical documents to back his claim that he’s been given a clean bill of health just months after being handed a death sentence.

“I have the medical records to show the evidence of what I’m saying,” Miller said. “Now it’s going to be interpreted differently by people everywhere, but I’ve researched and there are thousands of testimonies that you can go on the internet and see every day people doing this and it’s been going on for years.””               http://stlouis.cbslocal.com/2016/01/22/granite-city-man-claims-cannabis-oil-killed-his-incurable-cancer/

“Granite City Man Claims Cannabis Oil Killed His “Incurable” Cancer”  http://stlouis.suntimes.com/stl-news/7/139/238717/granite-city-man-claims-cannabis-oil-killed-his-incurable-cancer

http://www.thctotalhealthcare.com/category/cancer/

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

Biomed Central logo

“It has been previously demonstrated in several cancer models, that Dronabinol (THC) may have anti-tumor activity – however, controversial data exists for acute leukemia. We have anecdotal evidence that THC may have contributed to disease control in a patient with acute undifferentiated leukemia.

To test this hypothesis, we evaluated the antileukemic efficacy of THC in several leukemia cell lines and native leukemia blasts cultured ex vivo.

We here reveal a novel aspect of dronabinol, a cannabinoid derivative, which displays remarkable antiproliferative as well as proapoptotic efficacy in a distinct leukemia patient cohort – in vitro and in ex vivo native leukemia blasts. It has been previously reported that cannabinoids display anticancer properties. However, due to legal issues the use and exploration of such agents is highly limited in many countries.

Importantly, we demonstrate that antileukemic concentrations are achievable in vivo.

Our study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in a well defined subset of acute leukemia patients.”

http://www.ncbi.nlm.nih.gov/pubmed/26775260

http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-2029-8

Cannabinoids inhibit cellular respiration of human oral cancer cells.

Related image

“The primary cannabinoids, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and Delta(8)-tetrahydrocannabinol (Delta(8)-THC) are known to disturb the mitochondrial function and possess antitumor activities. These observations prompted us to investigate their effects on the mitochondrial O(2) consumption in human oral cancer cells (Tu183). This epithelial cell line overexpresses bcl-2 and is highly resistant to anticancer drugs. A rapid decline in the rate of respiration was observed when Delta(9)-THC or Delta(8)-THC was added to the cells. The inhibition was concentration-dependent, and Delta(9)-THC was the more potent of the two compounds. Anandamide (an endocannabinoid) was ineffective; suggesting the effects of Delta(9)-THC and Delta(8)-THC were not mediated by the cannabinoid receptors. These results show the cannabinoids are potent inhibitors of human oral cancer cells (Tu183) cellular respiration and are toxic to this highly malignant tumor.” http://www.ncbi.nlm.nih.gov/pubmed/20516734

https://www.karger.com/Article/Abstract/312686

http://www.thctotalhealthcare.com/category/oral-cancer/

Ligands for cannabinoid receptors, promising anticancer agents.

Image result for Life Sci.

“Cannabinoid compounds are unique to cannabis and provide some interesting biological properties.

These compounds along with endocannabinoids, a group of neuromodulator compounds in the body especially in brain, express their effects by activation of G-protein-coupled cannabinoid receptors, CB1 and CB2.

There are several physiological properties attributed to the endocannabinoids including pain relief, enhancement of appetite, blood pressure lowering during shock, embryonic development, and blocking of working memory.

On the other hand, activation of endocannabinoid system may be suppresses evolution and progression of several types of cancer.

According to the results of recent studies, CB receptors are over-expressed in cancer cell lines and application of multiple cannabinoid or cannabis-derived compounds reduce tumor size through decrease of cell proliferation or induction of cell cycle arrest and apoptosis along with desirable effect on decrease of tumor-evoked pain.

Therefore, modulation of endocannabinoid system by inhibition of fatty acid amide hydrolase (FAAH), the enzyme, which metabolized endocannabinoids, or application of multiple cannabinoid or cannabis-derived compounds, may be appropriate for the treatment of several cancer subtypes. This review focuses on how cannabinoid affect different types of cancers.”

http://www.ncbi.nlm.nih.gov/pubmed/26764235

http://www.thctotalhealthcare.com/category/cancer/

Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines.

“Quercetin, the major constituent of flavonoid and widely present in fruits and vegetables, is an attractive compound for cancer prevention due to its beneficial anti proliferative effects, showing a crucial role in the regulation of apoptosis and cell cycle signaling.

In vitro studies have demonstrated that quercetin specifically influences colon cancer cell proliferation.

Our experiments, using human colon adenocarcinoma cells, confirmed the anti proliferative effect of quercetin and gave intriguing new insight in to the knowledge of the mechanisms involved…

These findings open new perspectives for anticancer therapeutic strategies.”

http://www.ncbi.nlm.nih.gov/pubmed/25893829

“Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L.”  http://www.ncbi.nlm.nih.gov/pubmed/15688956

Cannabis ‘Can Reduce Tumour Growth’, Expert Says

“He believes chemicals in cannabis could be anti-cancer agents”

Cannabis

Marijuana is now used by cancer patients in some countries to ease the pain of their illness – but it might actually offer a cure.Guillermo Velasco of the Complutense University of Madrid says there is evidence that cannabinoids – chemicals in cannabis – actually reduced tumour growth in animals.But he says that there is little interest from pharmaceutical companies.

Velasco told Upworthy,, ‘One of the reasons why [it] is so complicated to promote clinical studies is that the active components of marijuana are natural products that cannot be patented and therefore there are few pharma companies interested in their clinical development.’

Earlier this year, the U.S. government admitted that the drug can shrink cancer cells in rodent studies.

In a page of official government advice, the U.S. government now says,, ‘Cannabis has been shown to kill cancer cells in the laboratory.’

The site says that the effect has so far been seen in rodent studies, and cautions,  ‘At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy.’’”  https://uk.news.yahoo.com/cannabis–can-reduce-tumour-growth—expert-says-120408138.html#pQEf8NO